| Literature DB >> 28254486 |
Michael L Curtin1, Marina A Pliushchev2, Huan-Qiu Li2, Maricel Torrent2, Justin D Dietrich2, Clarissa G Jakob2, Haizhong Zhu2, Hongyu Zhao2, Ying Wang2, Zhiqin Ji2, Richard F Clark2, Kathy A Sarris2, Sujatha Selvaraju2, Bailin Shaw2, Mikkel A Algire2, Yupeng He2, Paul L Richardson2, Ramzi F Sweis2, Chaohong Sun2, Gary G Chiang2, Michael R Michaelides2.
Abstract
Herein we disclose SAR studies of a series of dimethylamino pyrrolidines which we recently reported as novel inhibitors of the PRC2 complex through disruption of EED/H3K27me3 binding. Modification of the indole and benzyl moieties of screening hit 1 provided analogs with substantially improved binding and cellular activities. This work culminated in the identification of compound 2, our nanomolar proof-of-concept (PoC) inhibitor which provided on-target tumor growth inhibition in a mouse xenograft model. X-ray crystal structures of several inhibitors bound in the EED active-site are also discussed.Entities:
Keywords: Cancer; EED; PRC2; Protein-protein interaction inhibitor (PPI)
Mesh:
Substances:
Year: 2017 PMID: 28254486 DOI: 10.1016/j.bmcl.2017.02.030
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823